Recombinant Human VE-Cadherin Fc Chimera His-tag Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VE-Cadherin Fc Chimera His-tag Protein, CF Summary

• Details of Functionality: Measured by the ability of the immobilized protein to support the adhesion of BCE C/D‑1b bovine corneal endothelial cells. The ED₅₀ for this effect is 40-160 ng/mL.
  Optimal dilutions should be determined by each laboratory for each application.
• Source: Mouse myeloma cell line, NS0-derived human VE-Cadherin protein
  

  Human VE-Cadherin (Asp48-Gln593) Accession # P33151	IEGRMD	Human IgG1 (Pro100-Lys330)	6-His tag
  N-terminus			C-terminus

• Accession #: P33151
• N-terminal Sequence: Asp48
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: CDH5
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 89 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 116 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VE-Cadherin Fc Chimera His-tag Protein, CF

• 7B4 antigen
• 7B4
• cadherin 5, type 2 (vascular endothelium)
• cadherin 5, type 2, VE-cadherin (vascular epithelium)
• Cadherin-5
• CD144 antigen
• CD144
• CDH5
• endothelial-specific cadherin
• FLJ17376
• Vascular endothelial cadherin
• VECadherin
• VE-Cadherin

Background

VE-Cadherin, also known as Cadherin-5 and CD144, is a member of the atypical/type II subgroup of Cadherin homophilic adhesion proteins (1). Mature human VE-Cadherin is a 125-135 kDa transmembrane glycoprotein that consistis of a 552 amino acid (aa) extracellular domain (ECD) with five Ca⁺⁺-binding Cadherin domains, a 21 aa transmembrane segment, and a 164 aa cytoplasmic domain (2, 3). Within the ECD, human VE-Cadherin shares approximately 75% aa sequence identity with mouse and rat VE-Cadherin. A 90 kDa portion of the VE-Cadherin ECD can be shed in a metalloproteinase-dependent mechanism and may function as a VE-Cadherin antagonist (4, 5). VE-Cadherin is expressed on the surface of vascular endothelial cells (EC) from early in embryogenesis through adulthood as well as in the placenta, on hematopoietic cell progenitors, and on a subpopulation of hematopoietic stem cells (6-8). It is a major protein component of adherens junctions between cells of the endothelium (9). VE-Cadherin supports the extension and stabilization of existing vascular sprouts (10). VE-Cadherin also regulates or is regulated by VEGF R2, type I and type II TGF-beta receptors, and other endothelial junction proteins such as JAM-C, Claudin-5, and N-Cadherin (11-15). Elevated levels of soluble VE-Cadherin are found in the serum of myocardial infarction, angina pectoris, rheumatoid arthritis, and colorectal cancer patients (16-18).

1. Giannotta, M. et al. (2013) Dev. Cell 26:441.
2. Breviario, F. et al. (1995) Arterioscler. Throm. Vasc. Biol. 15:1229.
3. Geyer, H. et al. (1999) Glycobiology 9:915.
4. Herren, B. et al. (1998) Mol. Biol. Cell 9:1589.
5. Li, H. et al. (2010) Cancer Gene Ther. 17:700.
6. Breier, G. et al. (1996) Blood 87:630.
7. Ema, M. et al. (2006) Blood 108:4018.
8. Oberlin, E. et al. (2010) Blood 116:4444.
9. Lampugnani, M.G. et al. (1992) J. Cell Biol. 118:1511.
10. Perryn, E.D. et al. (2008) Dev. Biol. 313:545.
11. Gavard, J. and J.S. Gutkind (2006) Nat. Cell Biol. 8:1223.
12. Orlova, V.V. et al. (2006) J. Exp. Med. 203:2703.
13. Taddei, A. et al. (2008) Nat. Cell Biol. 10:923.
14. Luo, Y. and G.L. Radice (2005) J. Cell Biol. 169:29.
15. Rudini, N. et al. (2008) EMBO J. 27:993.
16. Soeki, T. et al. (2004) Circ. J. 68:1.
17. Sulkowska, M. et al. (2006) Tumori 92:67.
18. Sidibe, A. et al. (2012) Arthritis Rheum. 64:77.

Publications for VE-Cadherin (938-VC)(4)

Publications using 938-VC

• N Gioelli, LJ Neilson, N Wei, G Villari, W Chen, B Kuhle, M Ehling, F Maione, S Willox, S Brundu, D Avanzato, G Koulouras, M Mazzone, E Giraudo, XL Yang, D Valdembri, S Zanivan, G Serini Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability Nature Communications, 2022-07-20;13(1):4188. 2022-07-20 [PMID: 35858913] (Bioassay, Human)
• Zhang P, Feng S, Liu G, Wang H, Zhu H, Ren Q, Bai H, Fu C, Dong C Mutant B-Raf(V600E) Promotes Melanoma Paracellular Transmigration by Inducing Thrombin-mediated Endothelial Junction Breakdown. J Biol Chem, 2015-10-26;291(5):2087-106. 2015-10-26 [PMID: 26504080] (Bioassay, Human)
• Dunne E, Spring CM, Reheman A, Jin W, Berndt MC, Newman DK, Newman PJ, Ni H, Kenny D Cadherin 6 has a functional role in platelet aggregation and thrombus formation. Arterioscler. Thromb. Vasc. Biol., 2012-04-26;32(7):1724-31. 2012-04-26 [PMID: 22539596] (Bioassay, Human)
• Li X, Edholm D, Lanner F, Breier G, Farnebo F, Dimberg A, Claesson-Welsh L Lentiviral rescue of vascular endothelial growth factor receptor-2 expression in flk1-/- embryonic stem cells shows early priming of endothelial precursors. Stem Cells, 2007-08-16;25(12):2987-95. 2007-08-16 [PMID: 17702981] (Bioassay, Mouse)

Bioinformatics

• Gene Symbol: CDH5
• Uniprot:
  • P33151()